Drug Profile
Talditercept alfa - Bristol-Myers Squibb/Roche
Alternative Names: Anti-myostatin adnectin; BHV-2000; BMS-986089; Myostatin-inhibiting adnectin fusion protein; RG 6206; RO 7239361; Taldefgrobep alfaLatest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Adnexus Therapeutics
- Developer Biohaven Pharmaceuticals; Bristol-Myers Squibb; Roche
- Class Proteins; Recombinant fusion proteins
- Mechanism of Action Myostatin inhibitors; Type-II-B activin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Spinal muscular atrophy
- Phase I Metabolic disorders
- Discontinued Duchenne muscular dystrophy
Most Recent Events
- 13 Apr 2024 US FDA grants Rare Pediatric Disease Designation (RPDD) to Talditercept alfa for Spinal muscular atrophy
- 08 Jan 2024 Biohaven plans a phase II trial for Obesity in second quarter of 2024 (Biohaven Pharmaceuticals pipeline; August 2023)
- 14 Nov 2023 Biohaven plans a phase II trial for Metabolic disorders in 2024